news)

NEWS

Media Contacts:

Europe

Robert Sutherland
Mobile: +44  7917 551 666
Email: robert.sutherland@seqirus.com

United States

Polina Miklush
Mobile: +1 908 608 7170
Email: polina.miklush@seqirus.com

Asia Pacific

Melanie Kerin
Mobile: +61 (0) 417 436 329
Email: melanie.kerin@seqirus.com

Seqirus news releases

Seqirus news releases

New Data Demonstrate that FLUAD® (Influenza Vaccine, Adjuvanted) Significantly Reduces Hospitalization Risk for Adults 65+ Living in U.S. Nursing Homes Compared to Standard Trivalent Influenza Vaccine
09 Dec 2019

Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine (TIV)

Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
26 Sep 2019

The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative approaches.

Seqirus opens new Centre of Excellence in Amsterdam
23 Sep 2019

New laboratory and office space will enhance influenza vaccine research and development and help the company prepare for Brexit.

Seqirus and Laboratoire Arrow sign Distribution Agreement in France
17 Sep 2019

This news release is intended for Health Professional media only.

Seqirus starts on time delivery of flu vaccines to support NHS immunisation programmes across the UK
05 Sep 2019

This news release is intended for Health Professional media only.